1
40
2
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Citation List Month
November 2017 List
URL Address
<a href="https://link.springer.com/chapter/10.1007/978-3-319-33679-4_31" target="_blank" rel="noreferrer">https://link.springer.com/chapter/10.1007/978-3-319-33679-4_31</a>
Notes
<p>Using Smart Source Parsing<br />(pp Date of Publication: 2017</p>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Palliative Care
Publisher
An entity responsible for making the resource available
Pediatric Oncology
Date
A point or period of time associated with an event in the lifecycle of the resource
2017
Subject
The topic of the resource
Neoplasm; Palliative Therapy; 73-78-9 (lidocaine); 76-99-3 (methadone); 103-90-2 (paracetamol); 125-56-4 (methadone); 137-58-6 (lidocaine); 297-88-1 (methadone); 437-38-7 (fentanyl); 1095-90-5 (methadone); 8002-76-4 (opiate); 8008-60-4 (opiate); 12794-10-4 (benzodiazepine); 23142-53-2 (methadone); 24847-67-4 (lidocaine); 53663-61-9 (opiate); 56934-02-2 (lidocaine); 60142-96-3 (gabapentin); Acute Stress Disorder; Alcohol Consumption; Anticonvulsive Agent; Appetite; Benzodiazepine; Corticosteroid; Distress Syndrome; Dyspnea; Fentanyl; Gabapentin; Hair Loss; Health Care Personnel; Health Care System; Hospital; Human; Intensive Care Unit; Lidocaine; Major Depression; Medical Staff; Methadone; Mortality; Nausea And Vomiting; Obesity; Opiate; Paracetamol; Paralysis; Patient Care Planning; Priority Journal; Prostaglandin/ec [endogenous Compound]; Quality Of Life; Tracheostomy
Creator
An entity primarily responsible for making the resource
Wasilewski-Masker K; Howk T; Connelly E; Postovsky S; Brill P; Wrammert KC; Pillai R
Description
An account of the resource
Cancer is a leading cause of death in adolescents and young adults (AYAs) Wiener et al. (Pediatr Blood Cancer 60(5):715-718, 2013). Though most AYAs will survive, cancer will become incurable in 10-40 % Schrijvers and Meijnder (Cancer Treat Rev 33(7):616-621, 2007). Although the general philosophies of palliative care apply to AYAs, developmental considerations are unique to this group (Ferrari et al. J Clin Oncol Off J Am Soc Clin Oncol 28(32):4850-4857, 2010); Wein et al. J Clin Oncol Off J Am Soc Clin Oncol 28(32):4819-4824, 2010). The interaction of psychosocial, emotional, physical, and existential issues is essential to consider (Wein et al. J Clin Oncol Off J Am Soc Clin Oncol 28(32):4819-4824, 2010). The gaps in care experienced on both sides of the healthcare system between pediatric and adult medicine can be particularly impactful when delivering palliative care. The benefit of a multidisciplinary palliative care approach is widely appreciated as is the need to begin the process early in order to develop a trusting relationship (Wiener et al. Pediatr Blood Cancer 60(5):715-718, 2013; Baker et al. Pediatr Clin N Am 55(1):223-250, 2008; Ferris et al. J Clin Oncol Off J Am Soc Clin Oncol 27(18):3052-3058). Honest communication which supports autonomy is essential in discussions of their goals, worries, risks versus benefits of treatment, and advanced care planning (Clark and Fasciano Am J Hosp Palliat Care 32(1):101-111, 2015; Christenson et al. J Pediatr Health Care Off Publ Natl Assoc Pediatr Nurse Assoc Pract 24(5):286-291, 2010; Linebarger et al. Pediatr Clin N Am 61(4):785-796, 2014).
Identifier
An unambiguous reference to the resource within a given context
<a href="https://doi.org/10.1007/978-3-319-33679-4_31" target="_blank" rel="noreferrer">10.1007/978-3-319-33679-4_31</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
103-90-2 (paracetamol)
1095-90-5 (methadone)
125-56-4 (methadone)
12794-10-4 (benzodiazepine)
137-58-6 (lidocaine)
2017
23142-53-2 (methadone)
24847-67-4 (lidocaine)
297-88-1 (methadone)
437-38-7 (fentanyl)
53663-61-9 (opiate)
56934-02-2 (lidocaine)
60142-96-3 (gabapentin)
73-78-9 (lidocaine)
76-99-3 (methadone)
8002-76-4 (opiate)
8008-60-4 (opiate)
Acute Stress Disorder
Alcohol Consumption
Anticonvulsive Agent
Appetite
Benzodiazepine
Brill P
Connelly E
Corticosteroid
Distress Syndrome
Dyspnea
Fentanyl
Gabapentin
Hair Loss
Health Care Personnel
Health Care System
Hospital
Howk T
Human
Intensive Care Unit
Lidocaine
Major Depression
Medical Staff
Methadone
Mortality
Nausea And Vomiting
Neoplasm
November 2017 List
Obesity
Opiate
Palliative Therapy
Paracetamol
Paralysis
Patient Care Planning
Pediatric Oncology
Pillai R
Postovsky S
Priority Journal
Prostaglandin/ec [endogenous Compound]
Quality Of Life
Tracheostomy
Wasilewski-Masker K
Wrammert KC
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Citation List Month
September 2017 List
Notes
<p>Using Smart Source Parsing ( (no pagination), 2015. Article Number: CD010750. Date of Publication: Mar 2015</p>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Pharmacological Interventions For Pain In Children And Adolescents With Life-limiting Conditions
Publisher
An entity responsible for making the resource available
Cochrane Database Of Systematic Reviews
Date
A point or period of time associated with an event in the lifecycle of the resource
2017
Subject
The topic of the resource
Drug Efficacy; Neuropathic Pain/dt [drug Therapy]; Nociceptive Pain/dt [drug Therapy]; 52-26-6 (morphine); 57-27-2 (morphine); 73-78-9 (lidocaine); 76-42-6 (oxycodone); 76-57-3 (codeine); 76-99-3 (methadone); 94-09-7 (benzocaine); 94-24-6 (tetracaine); 103-90-2 (paracetamol); 124-90-3 (oxycodone); 125-56-4 (methadone); 133-16-4 (chloroprocaine); 136-47-0 (tetracaine); 137-58-6 (lidocaine); 297-88-1 (methadone); 437-38-7 (fentanyl); 1095-90-5 (methadone); 1134-47-0 (baclofen); 1333-08-0 (benzocaine); 2180-92-9 (bupivacaine); 3858-89-7 (chloroprocaine); 15307-79-6 (diclofenac); 15307-86-5 (diclofenac); 15687-27-1 (ibuprofen); 18010-40-7 (bupivacaine); 23142-53-2 (methadone); 24847-67-4 (lidocaine); 31121-93-4 (ibuprofen); 38396-39-3 (bupivacaine); 40391-99-9 (pamidronic Acid); 52485-79-7 (buprenorphine); 53152-21-9 (buprenorphine); 55750-21-5 (bupivacaine); 56934-02-2 (lidocaine); 57248-88-1 (pamidronic Acid); 66376-36-1 (alendronic Acid); 74103-06-3 (ketorolac); 79261-49-7 (ibuprofen); 527688-20-6 (ibuprofen); Alendronic Acid/ct [clinical Trial]; Alendronic Acid/dt [drug Therapy]; Analgesia; Baclofen/ct [clinical Trial]; Baclofen/dt [drug Therapy]; Benzocaine/ct [clinical Trial]; Benzocaine/dt [drug Therapy]; Bupivacaine/ct [clinical Trial]; Bupivacaine/dt [drug Therapy]; Buprenorphine/ct [clinical Trial]; Buprenorphine/dt [drug Therapy]; Cerebral Palsy; Chloroprocaine/ct [clinical Trial]; Chloroprocaine/dt [drug Therapy]; Codeine/ct [clinical Trial]; Codeine/dt [drug Therapy]; Diclofenac/ct [clinical Trial]; Diclofenac/dt [drug Therapy]; Drug Clearance; Drug Safety; Fentanyl/ct [clinical Trial]; Fentanyl/dt [drug Therapy]; Functional Status; Human; Ibuprofen/ct [clinical Trial]; Ibuprofen/dt [drug Therapy]; Ketorolac/ct [clinical Trial]; Ketorolac/dt [drug Therapy]; Length Of Stay; Lidocaine/ct [clinical Trial]; Lidocaine/dt [drug Therapy]; Methadone/ct [clinical Trial]; Methadone/dt [drug Therapy]; Morphine/ct [clinical Trial]; Morphine/dt [drug Therapy]; Neuropathic Pain/dt [drug Therapy]; Nociceptive Pain/dt [drug Therapy]; Osteogenesis Imperfecta; Oxycodone/ct [clinical Trial]; Oxycodone/dt [drug Therapy]; Pain Intensity; Pain Severity; Pamidronic Acid/ct [clinical Trial]; Pamidronic Acid/dt [drug Therapy]; Paracetamol/ct [clinical Trial]; Paracetamol/dt [drug Therapy]; Priority Journal; Psychological Well-being; Quality Of Life; Randomized Controlled Trial (topic); Review; Risk Benefit Analysis; Tetracaine/ct [clinical Trial]; Tetracaine/dt [drug Therapy]; Treatment Outcome
Creator
An entity primarily responsible for making the resource
Beecham E; Candy B; Howard R; McCulloch R; Laddie J; Rees H; Vickerstaff V; Bluebond-Langner M; Jones L
Description
An account of the resource
Background: Pain is one of the most common symptoms in children and young people (CYP) with life-limiting conditions (LLCs) which include a wide range of diagnoses including cancer. The current literature indicates that pain is not well managed, however the evidence base to guide clinicians is limited. There is a clear need for evidence from a systematic review to inform prescribing. Objectives: To evaluate the evidence on the effectiveness of different pharmacological interventions used for pain in CYP with LLCs. Search methods: The following electronic databases were searched up to December 2014: CENTRAL (in the Cochrane Library), MEDLINE, EMBASE, PsycINFO and CINAHL. In addition, we searched conference proceedings and reference lists of included studies. For completeness, we also contacted experts in the field. No language restrictions were applied. Selection criteria: Randomised controlled trials (RCTs), quasi-randomised studies and other studies that included a clearly defined comparator group were included. The studies investigated pharmacological treatments for pain associated with LLCs in CYP. The treatment included those specifically developed to treat pain and those that acted as an adjuvant, where the treatment was not primarily developed to treat pain but has pain relieving properties. The LLC was identified by its inclusion in the Richard Hain Directory of LLCs. Data collection and analysis: Citations were screened by five review authors. Data were extracted by one review author and checked by a second. Two review authors assessed the risk of bias of included studies. A sufficient number of studies using homogeneous outcomes was not identified so a meta-analysis was not possible. Main results: We identified 24,704 citations from our database search. Nine trials with 379 participants fulfilled our inclusion criteria. Participants had cerebral palsy (CP) in five of the studies and osteogenesis imperfecta (OI) in the other four. Participants across the trials ranged in age from 2 to 19 years. All studies, apart from one cross-over trial, were parallel designed RCTs. Three of the trials on CP evaluated intrathecal baclofen (ITB) and two botulinum toxin A (BoNT-A). All of the OI trials evaluated the use of bisphosphonates (two alendronate and one pamidronate). No trials were identified that evaluated a commonly used analgesic in this patient group. Pain was a secondary outcome in five of the eight identified studies. Overall the quality of the trials was mixed. Only one study involved over 100 participants. For the two ITB studies for pain in CP, in the same study population but assessed at different time points in their disease, both found an effect on pain favouring the intervention compared to the control group (standard care or placebo) (mean difference (MD) 4.20, 95% confidence interval (CI) 2.15 to 6.25; MD 26.60, 95% CI 2.61 to 50.59, respectively). In these studies most of the adverse events related to the procedure or device for administration rather than the drug, such as swelling at the pump site. In one trial there were also eight serious adverse effects; these included difficulty swallowing and an epileptic seizure. The trial did not state if these occurred in the intervention group. At follow-up in both BoNT-A trials there was no evidence of a difference in pain between the trial arms among CP participants. The adverse events in the BoNT-A trials mostly involved those who received the intervention drug and involved seizures. Gastrointestinal problems were the most frequent adverse event in those who received alendronate. The trial investigating pamidronate found no evidence of a difference in pain compared to the control group. No adverse events were reported in this trial. Authors' conclusions: Published, controlled evidence on the pharmacological interventions for pain in CYP with LLCs is limited. The evidence that is currently available evaluated pain largely as a secondary outcome and the drugs used were all adjuvants and not always commonly used in general paediatric palliative care for p
Identifier
An unambiguous reference to the resource within a given context
10.1002/14651858.CD010750.pub2
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
103-90-2 (paracetamol)
1095-90-5 (methadone)
1134-47-0 (baclofen)
124-90-3 (oxycodone)
125-56-4 (methadone)
133-16-4 (chloroprocaine)
1333-08-0 (benzocaine)
136-47-0 (tetracaine)
137-58-6 (lidocaine)
15307-79-6 (diclofenac)
15307-86-5 (diclofenac)
15687-27-1 (ibuprofen)
18010-40-7 (bupivacaine)
2017
2180-92-9 (bupivacaine)
23142-53-2 (methadone)
24847-67-4 (lidocaine)
297-88-1 (methadone)
31121-93-4 (ibuprofen)
38396-39-3 (bupivacaine)
3858-89-7 (chloroprocaine)
40391-99-9 (pamidronic Acid)
437-38-7 (fentanyl)
52-26-6 (morphine)
52485-79-7 (buprenorphine)
527688-20-6 (ibuprofen)
53152-21-9 (buprenorphine)
55750-21-5 (bupivacaine)
56934-02-2 (lidocaine)
57-27-2 (morphine)
57248-88-1 (pamidronic Acid)
66376-36-1 (alendronic Acid)
73-78-9 (lidocaine)
74103-06-3 (ketorolac)
76-42-6 (oxycodone)
76-57-3 (codeine)
76-99-3 (methadone)
79261-49-7 (ibuprofen)
94-09-7 (benzocaine)
94-24-6 (tetracaine)
Alendronic Acid/ct [clinical Trial]
Alendronic Acid/dt [drug Therapy]
Analgesia
Baclofen/ct [clinical Trial]
Baclofen/dt [drug Therapy]
Beecham E
Benzocaine/ct [clinical Trial]
Benzocaine/dt [drug Therapy]
Bluebond-Langner M
Bupivacaine/ct [clinical Trial]
Bupivacaine/dt [drug Therapy]
Buprenorphine/ct [clinical Trial]
Buprenorphine/dt [drug Therapy]
Candy B
Cerebral Palsy
Chloroprocaine/ct [clinical Trial]
Chloroprocaine/dt [drug Therapy]
Cochrane Database of Systematic Reviews
Codeine/ct [clinical Trial]
Codeine/dt [drug Therapy]
Diclofenac/ct [clinical Trial]
Diclofenac/dt [drug Therapy]
Drug Clearance
Drug Efficacy
Drug Safety
Fentanyl/ct [clinical Trial]
Fentanyl/dt [drug Therapy]
Functional Status
Howard R
Human
Ibuprofen/ct [clinical Trial]
Ibuprofen/dt [drug Therapy]
Jones L
Ketorolac/ct [clinical Trial]
Ketorolac/dt [drug Therapy]
Laddie J
Length Of Stay
Lidocaine/ct [clinical Trial]
Lidocaine/dt [drug Therapy]
McCulloch R
Methadone/ct [clinical Trial]
Methadone/dt [drug Therapy]
Morphine/ct [clinical Trial]
Morphine/dt [drug Therapy]
Neuropathic Pain/dt [drug Therapy]
Nociceptive Pain/dt [drug Therapy]
Osteogenesis Imperfecta
Oxycodone/ct [clinical Trial]
Oxycodone/dt [drug Therapy]
Pain Intensity
Pain Severity
Pamidronic Acid/ct [clinical Trial]
Pamidronic Acid/dt [drug Therapy]
Paracetamol/ct [clinical Trial]
Paracetamol/dt [drug Therapy]
Priority Journal
Psychological Well-being
Quality Of Life
Randomized Controlled Trial (topic)
Rees H
Review
Risk Benefit Analysis
September 2017 List
Tetracaine/ct [clinical Trial]
Tetracaine/dt [drug Therapy]
Treatment Outcome
Vickerstaff V